Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
X4 Pharmaceuticals Inc
XFOR | US
0.50
USD-0.02
-4.52%
XFOR | US
About X4 Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.50
Open
0.52
High
0.53
Low
0.49
X4 Pharmaceuticals Inc. a late-stage clinical biopharmaceutical company focuses on the research development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) which is in Phase III clinical trial for the treatment of patients with warts hypogammaglobulinemia infections and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002 a CXCR4 antagonist for the treatment of brain cancers; and X4P-003 a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co. Ltd. to develop manufacture and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston Massachusetts.
View LessXFOR | US
Risk
84.3
Sharpe
-0.51
Luna's Score
33/100
Recommendation
Sell
Luna says (XFOR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
98.9%1 month
84.3%3 months
73.7%6 months
88.8%Returns
Fundamental Ratios
PE
4.00
Fwd. PE
-
Price to book
0.93
Debt to equity
0.83
Debt to assets
0.37
Ent. to EBITDA
1.10
Ent. to rev.
50.27
PEG
-
Other Fundamentals
EBITDA
-123.18M
MarketCap
83.58M
MarketCap(USD)
83.58M
Div. yield
-
Op. margin
-6.02K
Erngs. growth
-
Rev. growth
-
Ret. on equity
21.77
Short ratio
18.82
Short perc.
8.12
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.17
Range1M
0.26
Range3M
0.43
Volumes: Market Activity
Rel. volume
1.16
Price X volume
682.30K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.10 | - | Expensive |
| Ent. to Revenue | 50.27 | - | Cheaper |
| PE Ratio | 4.00 | 41.03 | Cheaper |
| Price to Book | 0.93 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 73.68 | - | Par |
| Debt to Equity | 0.83 | -1.23 | Expensive |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 83.58M | - | Emerging |
